---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-26-000050"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2026-04-17T23:59:59+00:00"
generated_at: "2026-05-15T05:33:39.787710+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics announces retirement of three directors and repricing of underwater stock options

## Summary
- Directors David Pyott, Katharine Knobil, and Suzanne Bruhn will retire effective at the 2026 Annual Meeting; all departures are not due to any disagreements.
- Board approved repricing of employee stock options (including executive officers) to $1.33 per share, effective April 17, 2026.
- Repricing covers options granted on or before March 1, 2025 under the 2015, 2020, and 2022 equity plans; eligible participants must stay through a 12-18 month retention period.
- Affected executive officers include CEO Bernard Coulie, CFO Keith Cummings, CHRO Lily Cheung, COO Minnie Kuo, CTO Delphine Imbert, and SVP Tim Machajewski.
- Underwater options were repriced to retain talent without additional dilution or cash compensation.

## SEC filing metadata
- accession: 0001746473-26-000050
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2026-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000050/0001746473-26-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000050/plrx-20260414.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-26-000050
- JSON: https://secwatch.observer/filing/0001746473-26-000050.json
- Plain text: https://secwatch.observer/filing/0001746473-26-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.